

# **Breast Cancer Screening Tests Market Forecasts to 2030 – Global Analysis By Test Type (Blood Tests, Imaging Test, Genetic Test, Biopsy, Tomosynthesis and Other Test Types), Gender, End User and By Geography**

<https://marketpublishers.com/r/BACC60A1A0E7EN.html>

Date: February 2025

Pages: 150

Price: US\$ 4,150.00 (Single User License)

ID: BACC60A1A0E7EN

## **Abstracts**

According to Statistics MRC, the Global Breast Cancer Screening Tests Market is accounted for \$2.29 billion in 2024 and is expected to reach \$4.01 billion by 2030 growing at a CAGR of 9.8% during the forecast period. Breast cancer screening tests are medical procedures used to detect early signs of breast cancer in individuals who show no symptoms. The primary screening methods include mammography, ultrasound, MRI, and 3D mammography (tomosynthesis). These tests aim to identify abnormal growths or changes in breast tissue, allowing for early diagnosis and treatment. Regular screening helps improve survival rates by detecting tumours at an earlier, more treatable stage, especially in individuals at higher risk for breast cancer.

According to the European Breast Cancer Coalition 2023, breast cancer was the most commonly diagnosed cancer in Europe in 2023, with around 380,000 new cases, primarily among women.

Market Dynamics:

Driver:

Increasing awareness of early detection

Growing awareness of early detection is essential to the market expansion for breast cancer screening tests. Demand for screening services has increased dramatically as

more individuals realize how important it is to detect cancer in its early stages. Health organizations' campaigning, media attention, and educational efforts have highlighted the life-saving advantages of early identification. Participation in screening programs has increased as a result of this knowledge, particularly among high-risk groups. Numerous screening techniques, including mammography, MRI, and ultrasound, are being used by a wide range of demographics due to the fact that early identification through routine screening improves treatment results and survival rates.

#### Restraint:

##### Radiation exposure concerns

Concerns about radiation exposure present a major obstacle to the market for breast cancer screening technologies, especially when using low-dose X-rays in standard procedures like mammography. Even while the radiation used in mammograms is considered to be low and safe for the majority of women, prolonged exposure might cause health hazards, such as an elevated risk of cancer. Particularly for younger women or those with a family history of cancer, these worries may discourage some people from getting frequent checkups. Alternative, non-radiative screening techniques like MRI and ultrasound are now being investigated in an effort to lower these hazards and guarantee efficient early identification.

#### Opportunity:

##### Rising awareness of genetic risk factors

Growing awareness of genetic risks, especially those associated with mutations in the BRCA1 and BRCA2 genes, has led to an increase in the number of people choosing early screening and genetic testing. Women are encouraged to get regular screenings at a younger age because of this awareness, particularly those who have a family history of breast cancer. When paired with screening procedures like MRIs and mammograms, genetic counseling assists in identifying high-risk patients, facilitating early detection and proactive monitoring. The need for better screening techniques and genetic testing is increasing along with awareness.

#### Threat:

##### Shortage of skilled healthcare professionals

The lack of qualified medical personnel, especially radiologists and technicians, is a major obstacle in the market for breast cancer screening testing. It takes highly qualified specialists to accurately interpret screening data, such as mammograms, and their absence can cause delays in diagnosis and decreased screening efficacy. The lack of trained staff restricts access to timely tests in many areas, particularly in rural or underprivileged areas, which has a detrimental effect on early detection initiatives. Healthcare systems are further burdened by this scarcity, underscoring the necessity of funding educational initiatives and the creation of AI-powered diagnostic technologies to assist medical practitioners.

### Covid-19 Impact

The COVID-19 pandemic significantly disrupted the breast cancer screening tests market, as many healthcare facilities temporarily suspended routine screenings to prioritize COVID-19 care. This led to delays in early detection, potentially affecting patient outcomes. Additionally, lockdowns and fear of exposure to the virus discouraged individuals from seeking screening services. However, as healthcare systems adapt, there has been a gradual recovery with the implementation of safety measures, increased use of telemedicine, and a focus on resuming delayed screenings for early diagnosis.

The imaging test segment is expected to be the largest during the forecast period

The imaging test segment is estimated to be the largest, driven by advancements in diagnostic technologies, such as 3D mammography, MRI, and ultrasound. These imaging tests provide higher accuracy, early detection of tumours, and better differentiation between benign and malignant growths. Additionally, the increasing prevalence of breast cancer, along with rising awareness of early detection, fuels the adoption of imaging tests. Technological innovations, improved image resolution, and integration of artificial intelligence further enhance the effectiveness of imaging in breast cancer diagnosis.

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostic laboratories segment is anticipated to witness the highest CAGR during the forecast period, as they provide specialized diagnostic services using advanced technologies like mammography, ultrasound, and MRI. The increasing demand for accurate and early breast cancer detection fuels growth in diagnostic labs. Additionally,

improved healthcare infrastructure and rising awareness of breast cancer prevention contribute to higher patient volumes. Laboratories' ability to offer timely and precise diagnostic results further enhances their importance in the early detection and treatment of breast cancer.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to growing healthcare awareness, increasing breast cancer prevalence, and rising disposable incomes. Rapid urbanization and improvements in healthcare infrastructure are making screening services more accessible. Government initiatives and screening programs in countries like Japan, China, and India are promoting early detection. Additionally, a rising focus on women's health, coupled with advancements in diagnostic technologies, further boosts the adoption of breast cancer screening tests across the region.

Region with highest CAGR:

During the forecast period, the North America region is anticipated to register the highest CAGR, fueled by factors such as high healthcare standards, strong government support, and advanced medical technologies. The widespread availability of screening programs, including mammography and MRI, encourages early detection and preventive care. Rising awareness about breast cancer, coupled with increased health insurance coverage, promotes regular screenings. Additionally, the aging population, high disposable incomes, and access to cutting-edge diagnostic tools further contribute to the market's growth in North America.

Key players in the market

Some of the key players profiled in the Breast Cancer Screening Tests Market include GE Healthcare, Hologic, Inc., Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, Koninklijke Philips N.V., Fujifilm Holdings Corporation, IQM Diagnostics, Medtronic PLC, 3M Health Care, Samsung Medison Co., Ltd., Carestream Health, Inc., Inovio Pharmaceuticals, Inc., Volpara Health Technologies, Medimaps Group, Dilon Technologies, Inc., LumaVision, and Aurora Imaging Technology, Inc.

Key Developments:

In March 2024, Philips strengthens strategic partnership with Sim&Cure to expand

innovation in neurovascular therapy. Philips announced the expansion of its strategic partnership with Sim&Cure, a leading provider of advanced digital solutions for neurovascular therapy. The partnership between the two companies started 5 years ago.

In May 2024, Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, announced it has signed an agreement to acquire 100% of the shares of Sonio SAS, a fetal ultrasound AI software company.

In March 2024, GE Healthcare Wipro, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, today announced an investment of over INR8000 Crores in manufacturing output & local R&D over next 5 years.

#### Test Types Covered:

Blood Tests

Imaging Test

Genetic Test

Biopsy

Tomosynthesis

Other Test Types

#### Genders Covered:

Male

Female

#### End Users Covered:

Diagnostic Laboratories

Hospitals

Specialty Clinics

Cancer Institutes

Research Laboratories

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants

- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

#### Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

##### Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

##### Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

##### Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

## Contents

### **1 EXECUTIVE SUMMARY**

### **2 PREFACE**

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
  - 2.4.1 Data Mining
  - 2.4.2 Data Analysis
  - 2.4.3 Data Validation
  - 2.4.4 Research Approach
- 2.5 Research Sources
  - 2.5.1 Primary Research Sources
  - 2.5.2 Secondary Research Sources
  - 2.5.3 Assumptions

### **3 MARKET TREND ANALYSIS**

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19

### **4 PORTERS FIVE FORCE ANALYSIS**

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

### **5 GLOBAL BREAST CANCER SCREENING TESTS MARKET, BY TEST TYPE**

*Breast Cancer Screening Tests Market Forecasts to 2030 – Global Analysis By Test Type (Blood Tests, Imaging Te...*

- 5.1 Introduction
- 5.2 Blood Tests
- 5.3 Imaging Test
  - 5.3.1 Mammography
  - 5.3.2 Magnetic Resonance Imaging (MRI)
  - 5.3.3 PET Scan
  - 5.3.4 Ultrasound
- 5.4 Genetic Test
  - 5.4.1 Fluorescence In Situ Hybridization
  - 5.4.2 HER gene test
- 5.5 Biopsy
- 5.6 Tomosynthesis
- 5.7 Other Test Types

## **6 GLOBAL BREAST CANCER SCREENING TESTS MARKET, BY GENDER**

- 6.1 Introduction
- 6.2 Male
- 6.3 Female

## **7 GLOBAL BREAST CANCER SCREENING TESTS MARKET, BY END USER**

- 7.1 Introduction
- 7.2 Diagnostic Laboratories
- 7.3 Hospitals
- 7.4 Specialty Clinics
- 7.5 Cancer Institutes
- 7.6 Research Laboratories
- 7.7 Other End Users

## **8 GLOBAL BREAST CANCER SCREENING TESTS MARKET, BY GEOGRAPHY**

- 8.1 Introduction
- 8.2 North America
  - 8.2.1 US
  - 8.2.2 Canada
  - 8.2.3 Mexico
- 8.3 Europe

- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
  - 8.4.1 Japan
  - 8.4.2 China
  - 8.4.3 India
  - 8.4.4 Australia
  - 8.4.5 New Zealand
  - 8.4.6 South Korea
  - 8.4.7 Rest of Asia Pacific
- 8.5 South America
  - 8.5.1 Argentina
  - 8.5.2 Brazil
  - 8.5.3 Chile
  - 8.5.4 Rest of South America
- 8.6 Middle East & Africa
  - 8.6.1 Saudi Arabia
  - 8.6.2 UAE
  - 8.6.3 Qatar
  - 8.6.4 South Africa
  - 8.6.5 Rest of Middle East & Africa

## **9 KEY DEVELOPMENTS**

- 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 9.2 Acquisitions & Mergers
- 9.3 New Product Launch
- 9.4 Expansions
- 9.5 Other Key Strategies

## **10 COMPANY PROFILING**

- 10.1 GE Healthcare
- 10.2 Hologic, Inc.
- 10.3 Siemens Healthineers

- 10.4 Philips Healthcare
- 10.5 Canon Medical Systems Corporation
- 10.6 Koninklijke Philips N.V.
- 10.7 Fujifilm Holdings Corporation
- 10.8 IQM Diagnostics
- 10.9 Medtronic PLC
- 10.10 3M Health Care
- 10.11 Samsung Medison Co., Ltd.
- 10.12 Carestream Health, Inc.
- 10.13 Inovio Pharmaceuticals, Inc.
- 10.14 Volpara Health Technologies
- 10.15 Medimaps Group
- 10.16 Dilon Technologies, Inc.
- 10.17 LumaVision
- 10.18 Aurora Imaging Technology, Inc.

## List Of Tables

### LIST OF TABLES

Table 1 Global Breast Cancer Screening Tests Market Outlook, By Region (2022-2030) (\$MN)

Table 2 Global Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) (\$MN)

Table 3 Global Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) (\$MN)

Table 4 Global Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) (\$MN)

Table 5 Global Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) (\$MN)

Table 6 Global Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) (\$MN)

Table 7 Global Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) (\$MN)

Table 8 Global Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) (\$MN)

Table 9 Global Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) (\$MN)

Table 10 Global Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) (\$MN)

Table 11 Global Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) (\$MN)

Table 12 Global Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) (\$MN)

Table 13 Global Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) (\$MN)

Table 14 Global Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) (\$MN)

Table 15 Global Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) (\$MN)

Table 16 Global Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) (\$MN)

Table 17 Global Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) (\$MN)

Table 18 Global Breast Cancer Screening Tests Market Outlook, By End User

(2022-2030) (\$MN)

Table 19 Global Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) (\$MN)

Table 20 Global Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) (\$MN)

Table 21 Global Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) (\$MN)

Table 22 Global Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) (\$MN)

Table 23 Global Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) (\$MN)

Table 24 Global Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) (\$MN)

Table 25 North America Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) (\$MN)

Table 26 North America Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) (\$MN)

Table 27 North America Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) (\$MN)

Table 28 North America Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) (\$MN)

Table 29 North America Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) (\$MN)

Table 30 North America Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) (\$MN)

Table 31 North America Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) (\$MN)

Table 32 North America Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) (\$MN)

Table 33 North America Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) (\$MN)

Table 34 North America Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) (\$MN)

Table 35 North America Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) (\$MN)

Table 36 North America Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) (\$MN)

Table 37 North America Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) (\$MN)

Table 38 North America Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) (\$MN)

Table 39 North America Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) (\$MN)

Table 40 North America Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) (\$MN)

Table 41 North America Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) (\$MN)

Table 42 North America Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) (\$MN)

Table 43 North America Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) (\$MN)

Table 44 North America Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) (\$MN)

Table 45 North America Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) (\$MN)

Table 46 North America Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) (\$MN)

Table 47 North America Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) (\$MN)

Table 48 North America Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) (\$MN)

Table 49 Europe Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) (\$MN)

Table 50 Europe Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) (\$MN)

Table 51 Europe Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) (\$MN)

Table 52 Europe Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) (\$MN)

Table 53 Europe Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) (\$MN)

Table 54 Europe Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) (\$MN)

Table 55 Europe Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) (\$MN)

Table 56 Europe Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) (\$MN)

Table 57 Europe Breast Cancer Screening Tests Market Outlook, By Genetic Test

(2022-2030) (\$MN)

Table 58 Europe Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) (\$MN)

Table 59 Europe Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) (\$MN)

Table 60 Europe Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) (\$MN)

Table 61 Europe Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) (\$MN)

Table 62 Europe Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) (\$MN)

Table 63 Europe Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) (\$MN)

Table 64 Europe Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) (\$MN)

Table 65 Europe Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) (\$MN)

Table 66 Europe Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) (\$MN)

Table 67 Europe Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) (\$MN)

Table 68 Europe Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) (\$MN)

Table 69 Europe Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) (\$MN)

Table 70 Europe Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) (\$MN)

Table 71 Europe Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) (\$MN)

Table 72 Europe Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) (\$MN)

Table 73 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) (\$MN)

Table 74 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) (\$MN)

Table 75 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) (\$MN)

Table 76 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) (\$MN)

Table 77 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) (\$MN)

Table 78 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) (\$MN)

Table 79 Asia Pacific Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) (\$MN)

Table 80 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) (\$MN)

Table 81 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) (\$MN)

Table 82 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) (\$MN)

Table 83 Asia Pacific Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) (\$MN)

Table 84 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) (\$MN)

Table 85 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) (\$MN)

Table 86 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) (\$MN)

Table 87 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) (\$MN)

Table 88 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) (\$MN)

Table 89 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) (\$MN)

Table 90 Asia Pacific Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) (\$MN)

Table 91 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) (\$MN)

Table 92 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) (\$MN)

Table 93 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) (\$MN)

Table 94 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) (\$MN)

Table 95 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) (\$MN)

Table 96 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Other End

Users (2022-2030) (\$MN)

Table 97 South America Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) (\$MN)

Table 98 South America Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) (\$MN)

Table 99 South America Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) (\$MN)

Table 100 South America Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) (\$MN)

Table 101 South America Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) (\$MN)

Table 102 South America Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) (\$MN)

Table 103 South America Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) (\$MN)

Table 104 South America Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) (\$MN)

Table 105 South America Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) (\$MN)

Table 106 South America Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) (\$MN)

Table 107 South America Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) (\$MN)

Table 108 South America Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) (\$MN)

Table 109 South America Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) (\$MN)

Table 110 South America Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) (\$MN)

Table 111 South America Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) (\$MN)

Table 112 South America Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) (\$MN)

Table 113 South America Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) (\$MN)

Table 114 South America Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) (\$MN)

Table 115 South America Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) (\$MN)

Table 116 South America Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) (\$MN)

Table 117 South America Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) (\$MN)

Table 118 South America Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) (\$MN)

Table 119 South America Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) (\$MN)

Table 120 South America Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) (\$MN)

Table 121 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) (\$MN)

Table 122 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) (\$MN)

Table 123 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) (\$MN)

Table 124 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) (\$MN)

Table 125 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) (\$MN)

Table 126 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) (\$MN)

Table 127 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) (\$MN)

Table 128 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) (\$MN)

Table 129 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) (\$MN)

Table 130 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) (\$MN)

Table 131 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) (\$MN)

Table 132 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) (\$MN)

Table 133 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) (\$MN)

Table 134 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) (\$MN)

Table 135 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By

Gender (2022-2030) (\$MN)

Table 136 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) (\$MN)

Table 137 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) (\$MN)

Table 138 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) (\$MN)

Table 139 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) (\$MN)

Table 140 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) (\$MN)

Table 141 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) (\$MN)

Table 142 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) (\$MN)

Table 143 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) (\$MN)

Table 144 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) (\$MN)

## I would like to order

Product name: Breast Cancer Screening Tests Market Forecasts to 2030 – Global Analysis By Test Type (Blood Tests, Imaging Test, Genetic Test, Biopsy, Tomosynthesis and Other Test Types), Gender, End User and By Geography

Product link: <https://marketpublishers.com/r/BACC60A1A0E7EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BACC60A1A0E7EN.html>